Role of MEX3A in tumorigenesis: Mechanisms, tumor‑specific effects and therapeutic implications (Review)
- Authors:
- Lulu Tang
- Li Zhang
- Shun Yao
- Xin Li
- Yongfeng Wang
- Qian Liu
- Jiajia Li
- Guorong Wen
- Jiaxing An
- Hai Jin
- Jiaxing Zhu
- Biguang Tuo
-
Affiliations: Department of Gastroenterology, Digestive Disease Hospital, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou 563000, P.R. China - Published online on: July 7, 2025 https://doi.org/10.3892/ijmm.2025.5579
- Article Number: 138
-
Copyright: © Tang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
 |
|
Siegel RL, Kratzer TB, Giaquinto AN, Sung H and Jemal A: Cancer statistics, 2025. CA Cancer J Clin. 75:10–45. 2025. View Article : Google Scholar : PubMed/NCBI | |
|
Wang H, Wang T, Yan S, Tang J, Zhang Y, Wang L, Xu H and Tu C: Crosstalk of pyroptosis and cytokine in the tumor microenvironment: From mechanisms to clinical implication. Mol Cancer. 23:2682024. View Article : Google Scholar : PubMed/NCBI | |
|
Li J, Zhou W, Wang H, Huang M and Deng H: Exosomal circular RNAs in tumor microenvironment: An emphasis on signaling pathways and clinical opportunities. MedComm (2020). 5:e700192024. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang X, Tang B, Luo J, Yang Y, Weng Q, Fang S, Zhao Z, Tu J, Chen M and Ji J: Cuproptosis, ferroptosis and PANoptosis in tumor immune microenvironment remodeling and immunotherapy: Culprits or new hope. Mol Cancer. 23:2552024. View Article : Google Scholar : PubMed/NCBI | |
|
Zhu D, Pan W, Li H, Hua J, Zhang C and Zhao K: Innovative applications of bacteria and their derivatives in targeted tumor therapy. ACS Nano. 19:5077–5109. 2025. View Article : Google Scholar : PubMed/NCBI | |
|
Arcuri LJ and Americo AD: Treatment of relapsed/refractory multiple myeloma in the bortezomib and lenalidomide era: A systematic review and network meta-analysis. Ann Hematol. 100:725–734. 2021. View Article : Google Scholar | |
|
Glisovic T, Bachorik JL, Yong J and Dreyfuss G: RNA-binding proteins and post-transcriptional gene regulation. FEBS Lett. 582:1977–1986. 2008. View Article : Google Scholar | |
|
Bitaraf A, Razmara E, Bakhshinejad B, Yousefi H, Vatanmakanian M, Garshasbi M, Cho WC and Babashah S: The oncogenic and tumor suppressive roles of RNA-binding proteins in human cancers. J Cell Physiol. 236:6200–6224. 2021. View Article : Google Scholar | |
|
Buchet-Poyau K, Courchet J, Hir HL, Séraphin B, Scoazec JY, Duret L, Domon-Dell C, Freund JN and Billaud M: Identification and characterization of human Mex-3 proteins, a novel family of evolutionarily conserved RNA-binding proteins differentially localized to processing bodies. Nucleic Acids Res. 35:1289–1300. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Draper BW, Mello CC, Bowerman B, Hardin J and Priess JR: MEX-3 is a KH domain protein that regulates blastomere identity in early C. elegans embryos. Cell. 87:205–216. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Lederer M, Müller S, Glaß M, Bley N, Ihling C, Sinz A and Hüttelmaier S: Oncogenic potential of the dual-function protein MEX3A. Biology (Basel). 10:4152021.PubMed/NCBI | |
|
Hahn WC, Bader JS, Braun TP, Califano A, Clemons PA, Druker BJ, Ewald AJ, Fu H, Jagu S, Kemp CJ, et al: An expanded universe of cancer targets. Cell. 184:1142–1155. 2021. View Article : Google Scholar | |
|
Wang T and Zhang H: Exploring the roles and molecular mechanisms of RNA binding proteins in the sorting of noncoding RNAs into exosomes during tumor progression. J Adv Res. 65:105–123. 2024. View Article : Google Scholar | |
|
Elcheva IA, Gowda CP, Bogush D, Gornostaeva S, Fakhardo A, Sheth N, Kokolus KM, Sharma A, Dovat S, Uzun Y, et al: IGF2BP family of RNA-binding proteins regulate innate and adaptive immune responses in cancer cells and tumor microenvironment. Front Immunol. 14:12245162023. View Article : Google Scholar : PubMed/NCBI | |
|
Xu Y, Pan S, Chen H, Qian H, Wang Z and Zhu X: MEX3A suppresses proliferation and EMT via inhibiting Akt signaling pathway in cervical cancer. Am J Cancer Res. 11:1446–1462. 2021.PubMed/NCBI | |
|
Pereira B, Billaud M and Almeida R: RNA-binding proteins in cancer: Old players and new actors. Trends Cancer. 3:506–528. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Sun M, Tan Z, Lin K, Li X, Zhu J, Zhan L and Zheng H: Advanced progression for the heterogeneity and homeostasis of intestinal stem cells. Stem Cell Rev Rep. 19:2109–2119. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Jiang Z, Sun Z, Hu J, Li D, Xu X, Li M, Feng Z, Zeng S, Mao H and Hu C: Grass carp Mex3A promotes ubiquitination and degradation of RIG-I to inhibit innate immune response. Front Immunol. 13:9093152022. View Article : Google Scholar : PubMed/NCBI | |
|
Wang B, Hong Z, Zhao C, Bi Q, Yuan J, Chen J and Shen Y: The effects of MEX3A knockdown on proliferation, apoptosis and migration of osteosarcoma cells. Cancer Cell Int. 21:1972021. View Article : Google Scholar : | |
|
Zhang P, Su T and Zhang S: Comprehensive analysis of prognostic value of MEX3A and its relationship with immune infiltrates in ovarian cancer. J Immunol Res. 2021:55741762021. View Article : Google Scholar : PubMed/NCBI | |
|
Panzeri V, Manni I, Capone A, Naro C, Sacconi A, Di Agostino S, de Latouliere L, Montori A, Pilozzi E, Piaggio G, et al: The RNA-binding protein MEX3A is a prognostic factor and regulator of resistance to gemcitabine in pancreatic ductal adenocarcinoma. Mol Oncol. 15:579–595. 2021. View Article : Google Scholar | |
|
Barriga FM, Montagni E, Mana M, Mendez-Lago M, Hernando-Momblona X, Sevillano M, Guillaumet-Adkins A, Rodriguez-Esteban G, Buczacki SJA, Gut M, et al: Mex3a marks a slowly dividing subpopulation of Lgr5+ intestinal stem cells. Cell Stem Cell. 20:801–816.e7. 2017. View Article : Google Scholar | |
|
Joazeiro CA and Weissman AM: RING finger proteins: Mediators of ubiquitin ligase activity. Cell. 102:549–552. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Xie Q, Chu Y, Yuan W, Li Y, Li K, Wu X, Liu X, Xu R, Cui S and Qu X: Activation of insulin-like growth factor-1 receptor (IGF-1R) promotes growth of colorectal cancer through triggering the MEX3A-mediated degradation of RIG-I. Acta Pharm Sin B. 13:2963–2975. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Aizer A, Kafri P, Kalo A and Shav-Tal Y: The P body protein Dcp1a is hyper-phosphorylated during mitosis. PLoS One. 8:e497832013. View Article : Google Scholar | |
|
Wang JY, Liu YJ, Zhang XL, Liu YH, Jiang LL and Hu HY: PolyQ-expanded ataxin-2 aggregation impairs cellular processing-body homeostasis via sequestering the RNA helicase DDX6. J Biol Chem. 300:1074132024. View Article : Google Scholar : PubMed/NCBI | |
|
Tritschler F, Eulalio A, Truffault V, Hartmann MD, Helms S, Schmidt S, Coles M, Izaurralde E and Weichenrieder O: A divergent Sm fold in EDC3 proteins mediates DCP1 binding and P-body targeting. Mol Cell Biol. 27:8600–8611. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Chen RX, Xu SD, Deng MH, Hao SH, Chen JW, Ma XD, Zhuang WT, Cao JH, Lv YR, Lin JL, et al: Mex-3 RNA binding family member A (MEX3A)/circMPP6 complex promotes colorectal cancer progression by inhibiting autophagy. Signal Transduct Target Ther. 9:802024. View Article : Google Scholar : PubMed/NCBI | |
|
Bufalieri F, Caimano M, Severini LL, Basili I, Paglia F, Sampirisi L, Loricchio E, Petroni M, Canettieri G, Santoro A, et al: The RNA-Binding ubiquitin ligase MEX3A affects glioblastoma tumorigenesis by inducing ubiquitylation and degradation of RIG-I. Cancers (Basel). 12:3212020. View Article : Google Scholar | |
|
Xiao Y, Li Y, Shi D, Wang X, Dai S, Yang M, Kong L, Chen B, Huang X, Lin C, et al: MEX3C-mediated decay of SOCS3 mRNA promotes JAK2/STAT3 signaling to facilitate metastasis in hepatocellular carcinoma. Cancer Res. 82:4191–4205. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Liu X, Wang Y, Zhou G, Zhou J, Tian Z and Xu J: circGRAMD1B contributes to migration, invasion and epithelial-mesenchymal transition of lung adenocarcinoma cells via modulating the expression of SOX4. Funct Integr Genomics. 23:752023. View Article : Google Scholar : PubMed/NCBI | |
|
Liao Z, Hu C and Gao Y: Mechanisms modulating the activities of intestinal stem cells upon radiation or chemical agent exposure. J Radiat Res. 63:149–157. 2022. View Article : Google Scholar | |
|
Yang P, Zhang P and Zhang S: RNA-binding protein MEX3A interacting with DVL3 stabilizes Wnt/β-catenin signaling in endometrial carcinoma. Int J Mol Sci. 24:5922022. View Article : Google Scholar | |
|
Xu J, Chen S, Hao T, Liu G, Zhang K, Zhang C and He Y: MEX3A promotes colorectal cancer migration, invasion and EMT via regulating the Wnt/β-catenin signaling pathway. J Cancer Res Clin Oncol. 150:3192024. View Article : Google Scholar | |
|
Jiang S, Meng L, Chen X, Liu H, Zhang J, Chen F, Zheng J, Liu H, Wang F, Hu J and Li Z: MEX3A promotes triple negative breast cancer proliferation and migration via the PI3K/AKT signaling pathway. Exp Cell Res. 395:1121912020. View Article : Google Scholar : PubMed/NCBI | |
|
Xiang XX, Liu YL, Kang YF, Lu X and Xu K: MEX3A promotes nasopharyngeal carcinoma progression via the miR-3163/SCIN axis by regulating NF-κB signaling pathway. Cell Death Dis. 13:4202022. View Article : Google Scholar | |
|
Feng G, Wang P, Zhang H, Cheng S, Xing Y and Wang Y: MEX3A induces the development of thyroid cancer via targeting CREB1. Cell Biol Int. 47:1843–1853. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Pereira B, Le Borgne M, Chartier NT, Billaud M and Almeida R: MEX-3 proteins: Recent insights on novel post-transcriptional regulators. Trends Biochem Sci. 38:477–479. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Cheng LT, Tan GYT, Chang FP, Wang CK, Chou YC, Hsu PH and Hwang-Verslues WW: Core clock gene BMAL1 and RNA-binding protein MEX3A collaboratively regulate Lgr5 expression in intestinal crypt cells. Sci Rep. 13:175972023. View Article : Google Scholar : | |
|
Pereira B, Amaral AL, Dias A, Mendes N, Muncan V, Silva AR, Thibert C, Radu AG, David L, Máximo V, et al: MEX3A regulates Lgr5(+) stem cell maintenance in the developing intestinal epithelium. EMBO Rep. 21:e489382020. View Article : Google Scholar | |
|
Domingo-Muelas A, Duart-Abadia P, Morante-Redolat JM, Jordán-Pla A, Belenguer G, Fabra-Beser J, Paniagua-Herranz L, Pérez-Villalba A, Álvarez-Varela A, Barriga FM, et al: Post-transcriptional control of a stemness signature by RNA-binding protein MEX3A regulates murine adult neurogenesis. Nat Commun. 14:3732023. View Article : Google Scholar : | |
|
Santovito D, Henderson JM, Bidzhekov K, Triantafyllidou V, Jansen Y, Chen Z, Farina FM, Diagel A, Aslani M, Blanchet X, et al: Mex3a protects against atherosclerosis: Evidence from mice and humans. Circulation. 150:1213–1216. 2024. View Article : Google Scholar : PubMed/NCBI | |
|
Sun B, Li Q, Xiao X, Zhang J, Zhou Y, Huang Y, Gao J and Cao X: The loach haplotype-resolved genome and the identification of Mex3a involved in fish air breathing. Cell Genom. 4:1006702024. View Article : Google Scholar : | |
|
Santovito D, Egea V, Bidzhekov K, Natarelli L, Mourão A, Blanchet X, Wichapong K, Aslani M, Brunßen C, Horckmans M, et al: Autophagy unleashes noncanonical microRNA functions. Autophagy. 16:2294–2296. 2020. View Article : Google Scholar | |
|
Santovito D, Egea V, Bidzhekov K, Natarelli L, Mourão A, Blanchet X, Wichapong K, Aslani M, Brunßen C, Horckmans M, et al: Noncanonical inhibition of caspase-3 by a nuclear microRNA confers endothelial protection by autophagy in atherosclerosis. Sci Transl Med. 12:eaaz22942020. View Article : Google Scholar : PubMed/NCBI | |
|
Li H, Liang J, Wang J, Han J, Li S, Huang K and Liu C: Mex3a promotes oncogenesis through the RAP1/MAPK signaling pathway in colorectal cancer and is inhibited by hsa-miR-6887-3p. Cancer Commun (Lond). 41:472–491. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Wang Y, Liang Q, Lei K, Zhu Q, Zeng D, Liu Y, Lu Y, Kang T, Tang N, Huang L, et al: Targeting MEX3A attenuates metastasis of breast cancer via β-catenin signaling pathway inhibition. Cancer Lett. 521:50–63. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Wang CK, Chen TJ, Tan GYT, Chang FP, Sridharan S, Yu CA, Chang YH, Chen YJ, Cheng LT and Hwang-Verslues WW: MEX3A mediates p53 degradation to suppress ferroptosis and facilitate ovarian cancer tumorigenesis. Cancer Res. 83:251–263. 2023. View Article : Google Scholar : | |
|
Álvarez-Varela A, Novellasdemunt L, Barriga FM, Hernando-Momblona X, Cañellas-Socias A, Cano-Crespo S, Sevillano M, Cortina C, Stork D, Morral C, et al: Mex3a marks drug-tolerant persister colorectal cancer cells that mediate relapse after chemotherapy. Nat Cancer. 3:1052–1070. 2022. View Article : Google Scholar | |
|
Lu Y, Bi T, Zhou S and Guo M: MEX3A promotes angiogenesis in colorectal cancer via glycolysis. Libyan J Med. 18:22024462023. View Article : Google Scholar : PubMed/NCBI | |
|
de Sousa e Melo F, Kurtova AV, Harnoss JM, Kljavin N, Hoeck JD, Hung J, Anderson JE, Storm EE, Modrusan Z, Koeppen H, et al: A distinct role for Lgr5+ stem cells in primary and metastatic colon cancer. Nature. 543:676–680. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Pereira B, Sousa S, Barros R, Carreto L, Oliveira P, Oliveira C, Chartier NT, Plateroti M, Rouault JP, Freund JN, et al: CDX2 regulation by the RNA-binding protein MEX3A: impact on intestinal differentiation and stemness. Nucleic Acids Res. 41:3986–3999. 2013. View Article : Google Scholar | |
|
Ding J, He X, Luo W, Zhou W, Chen R, Cao G, Chen B and Xiong M: Development and validation of a pyroptosis-related signature for predicting prognosis in hepatocellular carcinoma. Front Genet. 13:8014192022. View Article : Google Scholar : PubMed/NCBI | |
|
Jiromaru R, Nakagawa T and Yasumatsu R: Advanced nasopharyngeal carcinoma: Current and emerging treatment options. Cancer Manag Res. 14:2681–2689. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Huang H, Yao Y, Deng X, Huang Z, Chen Y, Wang Z, Hong H, Huang H and Lin T: Immunotherapy for nasopharyngeal carcinoma: Current status and prospects (Review). Int J Oncol. 63:972023. View Article : Google Scholar : | |
|
Huang Y, Fang C, Shi JW, Wen Y and Liu D: Identification of hMex-3A and its effect on human bladder cancer cell proliferation. Oncotarget. 8:61215–61225. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Ouladan S and Orouji E: Chimeric antigen receptor-T cells in colorectal cancer: Pioneering new avenues in solid tumor immunotherapy. J Clin Oncol. 43:994–1005. 2025. View Article : Google Scholar : PubMed/NCBI | |
|
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021. View Article : Google Scholar | |
|
Zhan T, Betge J, Schulte N, Dreikhausen L, Hirth M, Li M, Weidner P, Leipertz A, Teufel A and Ebert MP: Digestive cancers: Mechanisms, therapeutics and management. Signal Transduct Target Ther. 10:242025. View Article : Google Scholar : PubMed/NCBI | |
|
Chen K, Collins G, Wang H and Toh JWT: Pathological features and prognostication in colorectal cancer. Curr Oncol. 28:5356–5383. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou X, Li S, Ma T, Zeng J, Li H, Liu X, Li F, Jiang B, Zhao M, Liu Z and Qin Y: MEX3A knockdown inhibits the tumorigenesis of colorectal cancer via modulating CDK2 expression. Exp Ther Med. 22:13432021. View Article : Google Scholar : | |
|
Pan L, Fan Y and Zhou L: SMYD2 epigenetically activates MEX3A and suppresses CDX2 in colorectal cancer cells to augment cancer growth. Clin Exp Pharmacol Physiol. 49:959–969. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Yang X, Li G, Tian Y, Wang X, Xu J, Liu R, Deng M, Shao C, Pan Y, Wu X, et al: Identifying the E2F3-MEX3A-KLF4 signaling axis that sustains cancer cells in undifferentiated and proliferative state. Theranostics. 12:6865–6882. 2022. View Article : Google Scholar | |
|
Wang L, Liu Y, Dai Y, Tang X, Yin T, Wang C, Wang T, Dong L, Shi M, Qin J, et al: Single-cell RNA-seq analysis reveals BHLHE40-driven pro-tumour neutrophils with hyperactivated glycolysis in pancreatic tumour microenvironment. Gut. 72:958–971. 2023. View Article : Google Scholar | |
|
Xie B, Lin J, Chen X, Zhou X, Zhang Y, Fan M, Xiang J, He N, Hu Z and Wang F: CircXRN2 suppresses tumor progression driven by histone lactylation through activating the hippo pathway in human bladder cancer. Mol Cancer. 22:1512023. View Article : Google Scholar : PubMed/NCBI | |
|
Colorectal cancer cells expressing Mex3a drive recurrence after chemotherapy. Nat Cancer. 3:1024–1025. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Siegel RL, Giaquinto AN and Jemal A: Cancer statistics, 2024. CA Cancer J Clin. 74:12–49. 2024. View Article : Google Scholar | |
|
Liu D, Li J, Xue Y, Zhao T, Jin Z, Dan W, Chen Z, Hu L and Sun S: Site-specific N-glycan alterations on haptoglobin as potential biomarkers for distinguishing intrahepatic cholangiocarcinoma from hepatocellular carcinoma. Int J Biol Macromol. 280:1355632024. View Article : Google Scholar : PubMed/NCBI | |
|
Feng M, Pan Y, Kong R and Shu S: Therapy of primary liver cancer. Innovation (Camb). 1:1000322020.PubMed/NCBI | |
|
Chan YT, Zhang C, Wu J, Lu P, Xu L, Yuan H, Feng Y, Chen ZS and Wang N: Biomarkers for diagnosis and therapeutic options in hepatocellular carcinoma. Mol Cancer. 23:1892024. View Article : Google Scholar | |
|
Yang JR, Tian YX, Li JE, Zhang Y, Fan YC and Wang K: Mex3a promoter hypomethylation can be utilized to diagnose HBV-associated hepatocellular carcinoma: A randomized controlled trial. Front Pharmacol. 15:13258692024. View Article : Google Scholar : PubMed/NCBI | |
|
Fang S, Zheng L, Chen X, Guo X, Ding Y, Ma J, Ding J, Chen W, Yang Y, Chen M, et al: MEX3A determines in vivo hepatocellular carcinoma progression and induces resistance to sorafenib in a Hippo-dependent way. Hepatol Int. 17:1500–1518. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Naro C, Ruta V and Sette C: Splicing dysregulation: Hallmark and therapeutic opportunity in pancreatic cancer. Trends Mol Med. 7:S1471–S4914. 2024. | |
|
Wang X, Shan YQ, Tan QQ, Tan CL, Zhang H, Liu JH, Ke NW, Chen YH and Liu XB: MEX3A knockdown inhibits the development of pancreatic ductal adenocarcinoma. Cancer Cell Int. 20:632020. View Article : Google Scholar : PubMed/NCBI | |
|
Hosein AN, Huang H, Wang Z, Parmar K, Du W, Huang J, Maitra A, Olson E, Verma U and Brekken RA: Cellular heterogeneity during mouse pancreatic ductal adenocarcinoma progression at single-cell resolution. JCI Insight. 5:e1292122019. View Article : Google Scholar | |
|
Liu Y, Xiong R, Xiao T, Xiong L, Wu J, Li J, Feng G, Song G and Liu K: SCARA5 induced ferroptosis to effect ESCC proliferation and metastasis by combining with ferritin light chain. BMC Cancer. 22:13042022. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou X, Li Y, Wang W, Wang S, Hou J, Zhang A, Lv B, Gao C, Yan Z, Pang D, et al: Regulation of hippo/YAP signaling and esophageal squamous carcinoma progression by an E3 ubiquitin ligase PARK2. Theranostics. 10:9443–9457. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Yang H, Wang F, Hallemeier CL, Lerut T and Fu J: Oesophageal cancer. Lancet. 404:1991–2005. 2024. View Article : Google Scholar : PubMed/NCBI | |
|
Deboever N, Jones CM, Yamashita K, Ajani JA and Hofstetter WL: Advances in diagnosis and management of cancer of the esophagus. BMJ. 385:e0749622024. View Article : Google Scholar : PubMed/NCBI | |
|
Wei L, Wang B, Hu L, Xu Y, Li Z, Shen Y and Huang H: MEX3A is upregulated in esophageal squamous cell carcinoma (ESCC) and promotes development and progression of ESCC through targeting CDK6. Aging (Albany NY). 12:21091–21113. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Nishito Y, Hasegawa M, Inohara N and Núñez G: MEX is a testis-specific E3 ubiquitin ligase that promotes death receptor-induced apoptosis. Biochem J. 396:411–417. 2006. View Article : Google Scholar | |
|
Jiang H, Zhang X, Luo J, Dong C, Xue J, Wei W, Chen J, Zhou J, Gao Y and Yang C: Knockdown of hMex-3A by small RNA interference suppresses cell proliferation and migration in human gastric cancer cells. Mol Med Rep. 6:575–580. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Xuan Y, Wang H, Yung MM, Chen F, Chan WS, Chan YS, Tsui SK, Ngan HY, Chan KK and Chan DW: SCD1/FADS2 fatty acid desaturases equipoise lipid metabolic activity and redox-driven ferroptosis in ascites-derived ovarian cancer cells. Theranostics. 12:3534–3552. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Chen W, Hu L, Lu X, Wang X, Zhao C, Guo C, Li X, Ding Y, Zhao H, Tong D, et al: The RNA binding protein MEX3A promotes tumor progression of breast cancer by post-transcriptional regulation of IGFBP4. Breast Cancer Res Treat. 201:353–366. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Yan L, Li H, An W, Wei W, Zhang X and Wang L: Mex-3 RNA binding MEX3A promotes the proliferation and migration of breast cancer cells via regulating RhoA/ROCK1/LIMK1 signaling pathway. Bioengineered. 12:5850–5858. 2021. View Article : Google Scholar | |
|
Sun H, Dai J, Chen M, Chen Q, Xie Q, Zhang W, Li G and Yan M: miR-139-5p was identified as biomarker of different molecular subtypes of breast carcinoma. Front Oncol. 12:8577142022. View Article : Google Scholar : PubMed/NCBI | |
|
Peng F, Wang L, Xiong L, Tang H, Du J and Peng C: Maackiain modulates miR-374a/GADD45A axis to inhibit triple-negative breast cancer initiation and progression. Front Pharmacol. 13:8068692022. View Article : Google Scholar : | |
|
Ning S, Li H, Qiao K, Wang Q, Shen M, Kang Y, Yin Y, Liu J, Liu L, Hou S, et al: Identification of long-term survival-associated gene in breast cancer. Aging (Albany NY). 12:20332–20349. 2020. View Article : Google Scholar | |
|
Jia R, Weng Y, Li Z, Liang W, Ji Y, Liang Y and Ning P: Bioinformatics analysis identifies IL6ST as a potential tumor suppressor gene for triple-negative breast cancer. Reprod Sci. 28:2331–2341. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Webb PM and Jordan SJ: Global epidemiology of epithelial ovarian cancer. Nat Rev Clin Oncol. 21:389–400. 2024. View Article : Google Scholar | |
|
Li F, Zhao C, Diao Y, Wang Z, Peng J, Yang N, Qiu C, Kong B and Li Y: MEX3A promotes the malignant progression of ovarian cancer by regulating intron retention in TIMELESS. Cell Death Dis. 13:5532022. View Article : Google Scholar : PubMed/NCBI | |
|
Wei Y, Chen Z, Li Y and Song K: The splicing factor WBP11 mediates MCM7 intron retention to promote the malignant progression of ovarian cancer. Oncogene. 43:1565–1578. 2024. View Article : Google Scholar | |
|
Konstantinopoulos PA and Matulonis UA: Clinical and translational advances in ovarian cancer therapy. Nat Cancer. 4:1239–1257. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Liang J, Li H, Han J, Jiang J, Wang J, Li Y, Feng Z, Zhao R, Sun Z, Lv B and Tian H: Mex3a interacts with LAMA2 to promote lung adenocarcinoma metastasis via PI3K/AKT pathway. Cell Death Dis. 11:6142020. View Article : Google Scholar | |
|
Zhang M, Cheng S, Jin Y, Zhao Y and Wang Y: Roles of CA125 in diagnosis, prediction, and oncogenesis of ovarian cancer. Biochim Biophys Acta Rev Cancer. 1875:1885032021. View Article : Google Scholar : PubMed/NCBI | |
|
Francoeur AA, Monk BJ and Tewari KS: Treatment advances across the cervical cancer spectrum. Nat Rev Clin Oncol. 22:182–199. 2025. View Article : Google Scholar | |
|
Yousaf S, Shehzadi A, Ahmad M, Asrar A, Ahmed I, Iqbal HMN and Bule MH: Recent advances in HPV biotechnology: Understanding host-virus interactions and cancer progression-a review. Int J Surg. 110:8025–8036. 2024. View Article : Google Scholar : | |
|
Liu Y, Xu Y, Jiang W, Ji H, Wang ZW and Zhu X: Discovery of key genes as novel biomarkers specifically associated with HPV-negative cervical cancer. Mol Ther Methods Clin Dev. 21:492–506. 2021. View Article : Google Scholar | |
|
Nelson CW and Mirabello L: Human papillomavirus genomics: Understanding carcinogenicity. Tumour Virus Res. 15:2002582023. View Article : Google Scholar : | |
|
Roesch-Dietlen F, Cano-Contreras AD, Sánchez-Maza YJ, Espinosa-González JM, Vázquez-Prieto MÁ, Valdés-de la O EJ, Díaz-Roesch F, Carrasco-Arroniz MÁ, Cruz-Palacios A, Grube-Pagola P, et al: Frequency of human papillomavirus infection in patients with gastrointestinal cancer. Rev Gastroenterol Mex (Engl Ed). 83:253–258. 2018.In English, Spanish. | |
|
Rous FA, Singhi EK, Sridhar A, Faisal MS and Desai A: Lung cancer treatment advances in 2022. Cancer Invest. 41:12–24. 2023. View Article : Google Scholar | |
|
Meyer ML, Peters S, Mok TS, Lam S, Yang PC, Aggarwal C, Brahmer J, Dziadziuszko R, Felip E, Ferris A, et al: Lung cancer research and treatment: Global perspectives and strategic calls to action. Ann Oncol. 35:1088–1104. 2024. View Article : Google Scholar | |
|
Zhang M, Cao L, Hou G, Lv X and Deng J: Investigation of the potential correlation between RNA-binding proteins in the evolutionarily conserved MEX3 family and non-small-cell lung cancer. Mol Biotechnol. 65:1263–1274. 2023. View Article : Google Scholar | |
|
Kang S, Ni Y, Lan K and Lv F: Hsa_circ_0008133 contributes to lung cancer progression by promoting glycolysis metabolism through the miR-760/MEX3A axis. Environ Toxicol. 39:3014–3025. 2024. View Article : Google Scholar : PubMed/NCBI | |
|
de Melo SM, da Silva ME, Torloni MR, Riera R, De Cicco K, Latorraca CO and Pinto ACPN: Anti-PD-1 and anti-PD-L1 antibodies for glioma. Cochrane Database Syst Rev. 1:CD0125322025.PubMed/NCBI | |
|
Cella E, Bosio A, Persico P, Caccese M, Padovan M, Losurdo A, Maccari M, Cerretti G, Ius T, Minniti G, et al: Corrigendum to 'PARP inhibitors in gliomas: Mechanisms of action, current trends and future perspectives' [Cancer Treat Rev. 131(2024) 102850]. Cancer Treat Rev. 132:1028662025. View Article : Google Scholar | |
|
Yang C, Zhan H, Zhao Y, Wu Y, Li L and Wang H: MEX3A contributes to development and progression of glioma through regulating cell proliferation and cell migration and targeting CCL2. Cell Death Dis. 12:142021. View Article : Google Scholar : PubMed/NCBI | |
|
Gan T, Wang Y, Xie M, Wang Q, Zhao S, Wang P, Shi Q, Qian X, Miao F, Shen Z and Nie E: MEX3A impairs DNA mismatch repair signaling and mediates acquired temozolomide resistance in glioblastoma. Cancer Res. 82:4234–4246. 2022. View Article : Google Scholar | |
|
Boucai L, Zafereo M and Cabanillas ME: Thyroid cancer: A review. JAMA. 331:425–435. 2024. View Article : Google Scholar | |
|
Ma Y, Yin S, Liu XF, Hu J, Cai N, Zhang XB, Fu L, Cao XC and Yu Y: Comprehensive analysis of the functions and prognostic value of RNA-binding proteins in thyroid cancer. Front Oncol. 11:6250072021. View Article : Google Scholar | |
|
Qin H, Ni H, Liu Y, Yuan Y, Xi T, Li X and Zheng L: RNA-binding proteins in tumor progression. J Hematol Oncol. 13:902020. View Article : Google Scholar : PubMed/NCBI | |
|
Muciño-Hernández MI, Montoya-Fuentes H, Ochoa-Plascencia MR, Vázquez-Camacho G, Morales-Jeanhs EA, Bencomo-Álvarez AE, Chejfec-Ciociano JM, Fuentes-Orozco C, Barbosa-Camacho FJ and González-Ojeda A: Molecular identification of human papillomavirus DNA in thyroid neoplasms: Association or serendipity? Cureus. 13:e145782021. | |
|
Chen KR, Yang CY, Shu SG, Lo YC, Lee KW, Wang LC, Chen JB, Shih MC, Chang HC, Hsiao YJ, et al: Endosomes serve as signaling platforms for RIG-I ubiquitination and activation. Sci Adv. 10:eadq06602024. View Article : Google Scholar : PubMed/NCBI | |
|
Helms MW, Jahn-Hofmann K, Gnerlich F, Metz-Weidmann C, Braun M, Dietert G, Scherer P, Grandien K, Theilhaber J, Cao H, et al: Utility of the RIG-I agonist triphosphate RNA for melanoma therapy. Mol Cancer Ther. 18:2343–2356. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Vogel GF, Ebner HL, de Araujo MEG, Schmiedinger T, Eiter O, Pircher H, Gutleben K, Witting B, Teis D, Huber LA and Hess MW: Ultrastructural morphometry points to a new role for LAMTOR2 in regulating the endo/lysosomal system. Traffic. 16:617–634. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Lin LL, Liu ZZ, Tian JZ, Zhang X, Zhang Y, Yang M, Zhong HC, Fang W, Wei RX and Hu C: Integrated analysis of nine prognostic RNA-binding proteins in soft tissue sarcoma. Front Oncol. 11:6330242021. View Article : Google Scholar : PubMed/NCBI | |
|
Solt CM, Hill JL, Vanderpool K and Foster MT: Obesity-induced immune dysfunction and immunosuppression: TEM observation of visceral and subcutaneous lymph node microarchitecture and immune cell interactions. Horm Mol Biol Clin Investig. 39/j/hmbci.2019.39.issue-2/hmbci-2018-0083/hmbci-2018-0083.xml. 2019. | |
|
Yang D, Jiao Y, Li Y and Fang X: Clinical characteristics and prognostic value of MEX3A mRNA in liver cancer. PeerJ. 8:e82522020. View Article : Google Scholar : PubMed/NCBI | |
|
Ji PX, Zhang P, Zhou HL, Yu H and Fu Y: MEX3A promotes cell proliferation by regulating the RORA/β-catenin pathway in hepatocellular carcinoma. World J Gastrointest Oncol. 17:1020842025. View Article : Google Scholar | |
|
Shi X, Sun Y, Zhang Y, Wang W, Xu J, Guan Y, Ding Y and Yao Y: MEX3A promotes development and progression of breast cancer through regulation of PIK3CA. Exp Cell Res. 404:1125802021. View Article : Google Scholar | |
|
Zhang Y, Zhang Y, Song J, Cheng X, Zhou C, Huang S, Zhao W, Zong Z and Yang L: Targeting the 'tumor microenvironment': RNA-binding proteins in the spotlight in colorectal cancer therapy. Int Immunopharmacol. 131:1118762024. View Article : Google Scholar | |
|
Li M, Fan X, Zhao J and Wang D: Establishment and validation of a four-stress granule-related gene signature in hepatocellular carcinoma. J Clin Transl Hepatol. 12:1–14. 2024. View Article : Google Scholar | |
|
Yang L, Wang C, Li F, Zhang J, Nayab A, Wu J, Shi Y and Gong Q: The human RNA-binding protein and E3 ligase MEX-3C binds the MEX-3-recognition element (MRE) motif with high affinity. J Biol Chem. 292:16221–16234. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Dong P, Taheri M and Wang F: Editorial: Interplay between RNA-binding proteins and non-coding RNAs in tumor therapeutic resistance. Front Oncol. 13:12011222023. View Article : Google Scholar | |
|
Huang Z, Xu E, Ma X, Wang Y, Zhu J, Zhu K, Hu J and Zhang C: Low NT5DC2 expression predicts favorable prognosis and suppresses soft tissue sarcoma progression via ECM-receptor interaction pathway. Transl Oncol. 44:1019372024. View Article : Google Scholar | |
|
Shi JW and Huang Y: Mex3a expression and survival analysis of bladder urothelial carcinoma. Oncotarget. 8:54764–54774. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang J, Liu L, Wang Z, Hou M, Dong Z, Yu J, Sun R and Cui G: Ubiquitin-proteasome system-based signature to predict the prognosis and drug sensitivity of hepatocellular carcinoma. Front Pharmacol. 14:11729082023. View Article : Google Scholar | |
|
Liu H, Tang L, Li Y, Xie W, Zhang L, Tang H, Xiao T, Yang H, Gu W, Wang H and Chen P: Nasopharyngeal carcinoma: Current views on the tumor microenvironment's impact on drug resistance and clinical outcomes. Mol Cancer. 23:202024. View Article : Google Scholar : PubMed/NCBI |
